CELL PRODUCT FOR TREATING AND CORRECTING HEPATIC IMPAIRMENT Russian patent published in 2014 - IPC C12N5/00 C12N5/02 C12N5/07 C12N5/71 C12N5/797 A61K35/12 A61K35/55 A61P1/16 

FIELD: medicine.

SUBSTANCE: invention refers to medicine and cell technologies. What is presented is a cell product containing a population of sub-mandibular salivary duct stem cells described by the phenotype CD49f+/EpCAM+ and changing an expression profile for 1AAT+/PEPCK+/G6P+/TDO+/CYP P4503A13+ after the treatment with valproic acid in the concentration of 0.1-40 mM and cultivation in collagen gel, as well as gaining the capacity to synthetise urea and albumin.

EFFECT: invention allows providing the effective recovery of the insufficient synthetic and detoxification hepatic function accompanying acute and chronic hepatic failure when used both in artificial liver apparatuses, and in the direct transplantation into the affected liver, and can be used for a cell replacement therapy of a wide spectrum of acute and chronic hepatic pathologies, including treating cirrhosis, acute and chronic hepatic failure, as well as for the recovery of the synthetic and detoxification hepatic functions when used as an active cell component in extracorporeal liver apparatuses.

2 tbl, 3 ex